Anti-ICOS Monoclonal Antibody MEDI-570

Phase 1Biologic

Anti-ICOS Monoclonal Antibody MEDI-570 is one of 20 biologic programs targeting Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Primary Cutaneous T-Cell Non-Hodgkin LymphomaActive, not recruiting

Angioimmunoblastic T-Cell LymphomaActive, not recruiting

Advanced Primary Cutaneous T-Cell Non-Hodgkin LymphomaPhase 1

Active, not recruiting

Angioimmunoblastic T-Cell LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Angioimmunoblastic T-Cell Lymphoma

#DrugCompanyPhaseTrials

Gemzar

Istodax

Treanda

AAzurity Pharmaceuticals

Fludara

1 5

Adriamycin

Pfizer

Phase 2

1 6

Oncovin

Eli Lilly

Phase 2

1 7

Thalomid

Bristol-Myers Squibb

Phase 2

1 8

Neoral

Novartis

Phase 2

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 2

2 10

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

NCT02520791

Clinical

Trials by Indication[1]

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma1 trial

A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02520791·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti-ICOS Monoclonal Antibody MEDI-570. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-ICOS Monoclonal Antibody MEDI-570 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-ICOS Monoclonal Antibody MEDI-570. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

Anti-ICOS Monoclonal Antibody MEDI-570

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News